Skip to main content
Premium Trial:

Request an Annual Quote

John Runkel, Deborah Day Barbara

Premium
Affymetrix has hired John Runkel to be executive VP and general counsel. Runkel formerly was senior VP of business development at Intuitive Surgical, a corporate secretary at VISX, and a managing partner for a law firm in San Francisco.
 

 
Deborah Day Barbara has been named VP of business development at Strategic Diagnostics. Day previously was VP of business development and licensing at Ore Pharmaceuticals and she also served as senior director of business and technology development for Johns Hopkins University. Barbara also was involved in sales for a decade at Amersham Life Sciences.

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.